Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Werner Scheithauer

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108460887. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper

Papers 14

  1. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. Co-author DOI 10.3390/jcm9030648↗
  2. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Co-author DOI 10.1177/1756284819877635↗
  3. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre pha… Co-author DOI 10.1177/1758835918818351↗
  4. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. Co-author DOI 10.1177/1758835919853196↗
  5. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  6. Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel. Co-author DOI 10.1038/s41598-017-04743-0↗
  7. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Co-author DOI 10.2147/ott.s124097↗
  8. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. Co-author DOI 10.21037/jgo.2016.01.03↗
  9. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.107↗
  10. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Co-author DOI 10.1093/jnci/dju413↗
  11. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with meta… Co-author DOI 10.1634/theoncologist.2014-0394↗
  12. Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression. Last author DOI 10.1111/eci.12329↗
  13. Clinical benefit response in pancreatic cancer trials revisited. Co-author DOI 10.1159/000357965↗
  14. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Co-author DOI 10.1111/eci.12042↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gerald W. Prager · 5 shared papers, 2016–2020 · strength 0.47
  2. Matthias Unseld · 3 shared papers, 2017–2020 · strength 0.31
  3. Markus Kieler · 3 shared papers, 2017–2020 · strength 0.31
  4. Daniela Bianconi · 3 shared papers, 2017–2020 · strength 0.31
  5. Richard Herrmann · 3 shared papers, 2014–2019 · strength 0.20
  6. Bengt L. G. Glimelius · 3 shared papers, 2014–2019 · strength 0.20
  7. David Goldstein · 4 shared papers, 2015–2018 · strength 0.19
  8. Martin Schindl · 2 shared papers, 2016–2020 · strength 0.18
  9. Volker Kunzmann · 3 shared papers, 2015–2017 · strength 0.17
  10. Josep M. Tabernero · 3 shared papers, 2015–2017 · strength 0.16
  11. Gyorgy Bodoky · 2 shared papers, 2014–2019 · strength 0.14
  12. Alfredo Romano · 3 shared papers, 2015–2016 · strength 0.14
  13. Daniel D. Von Hoff · 3 shared papers, 2015–2016 · strength 0.14
  14. Michele Reni · 2 shared papers, 2017–2018 · strength 0.13
  15. Christoph Carl Zielinski · 2 shared papers, 2016–2017 · strength 0.12
  16. Teresa Mercade Macarulla · 2 shared papers, 2016–2018 · strength 0.11
  17. Ramesh K. Ramanathan · 2 shared papers, 2015–2016 · strength 0.10
  18. Paul Martin Putora · 1 shared paper, 2019 · strength 0.10
  19. Wolfgang Eisterer · 1 shared paper, 2019 · strength 0.10
  20. Markus Glatzer · 1 shared paper, 2019 · strength 0.10
  21. Richard Greil · 1 shared paper, 2019 · strength 0.10
  22. Pascal R. Hammel · 2 shared papers, 2015–2016 · strength 0.10
  23. Jean‐Luc Van Laethem · 2 shared papers, 2015–2018 · strength 0.09
  24. Peter Brauchli · 1 shared paper, 2019 · strength 0.09
  25. Piera Gargiulo · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.